TY - JOUR
T1 - Effects of hyperglycemia on quantitative liver functions by the galactose load test in diabetic rats
AU - Young, Ton Ho
AU - Tang, Hung Shang
AU - Lee, Herng Sheng
AU - Hsiong, Cheng Huei
AU - Hu, Oliver Yoa Pu
PY - 2007/9/1
Y1 - 2007/9/1
N2 - Blood galactose clearance after an intravenous galactose load has been widely used as a quantitative liver function test. We have developed a novel quantitative rat liver function test, the galactose single point (GSP) method, to assess residual liver function with various injuries by measuring single time point galactose concentration in blood after an intravenous bolus injection of galactose. The goal of this study was to evaluate the influence of nonhepatic factors such as hyperglycemia on GSP and galactose elimination capacity (GEC) in rats. Four groups of animal studies were carried out, as follows: (1) normal control (NC), (2) streptozotocin-induced diabetes (DM), (3) carbon tetrachloride-induced hepatotoxicity (CCl4), and (4) streptozotocin-induced diabetes with CCl4-induced hepatotoxicity (DM + CCl4). The serum glucose levels in the diabetic groups (DM and DM + CCl4) were significantly increased compared with the NC and CCl4 groups (P < .001). A significant increase in hepatic activities of aspartate aminotransferase and alanine aminotransferase was observed in the CCl4-treated groups (CCl4 and DM + CCl4) compared with the NC and DM groups (P < .001). In comparison with the NC group, the values of GSP and GEC in the diabetic groups (DM and DM + CCl4) were significantly reduced (P < .001) and increased (P < .01), respectively. Galactose single point had highly significant correlations with GEC (P < .001). These results suggest that galactose metabolism tests-as quantitative parameters of liver function-should be interpreted with caution in the condition of a significant hyperglycemia.
AB - Blood galactose clearance after an intravenous galactose load has been widely used as a quantitative liver function test. We have developed a novel quantitative rat liver function test, the galactose single point (GSP) method, to assess residual liver function with various injuries by measuring single time point galactose concentration in blood after an intravenous bolus injection of galactose. The goal of this study was to evaluate the influence of nonhepatic factors such as hyperglycemia on GSP and galactose elimination capacity (GEC) in rats. Four groups of animal studies were carried out, as follows: (1) normal control (NC), (2) streptozotocin-induced diabetes (DM), (3) carbon tetrachloride-induced hepatotoxicity (CCl4), and (4) streptozotocin-induced diabetes with CCl4-induced hepatotoxicity (DM + CCl4). The serum glucose levels in the diabetic groups (DM and DM + CCl4) were significantly increased compared with the NC and CCl4 groups (P < .001). A significant increase in hepatic activities of aspartate aminotransferase and alanine aminotransferase was observed in the CCl4-treated groups (CCl4 and DM + CCl4) compared with the NC and DM groups (P < .001). In comparison with the NC group, the values of GSP and GEC in the diabetic groups (DM and DM + CCl4) were significantly reduced (P < .001) and increased (P < .01), respectively. Galactose single point had highly significant correlations with GEC (P < .001). These results suggest that galactose metabolism tests-as quantitative parameters of liver function-should be interpreted with caution in the condition of a significant hyperglycemia.
UR - http://www.scopus.com/inward/record.url?scp=34547662258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547662258&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2007.05.002
DO - 10.1016/j.metabol.2007.05.002
M3 - Article
C2 - 17697871
AN - SCOPUS:34547662258
SN - 0026-0495
VL - 56
SP - 1265
EP - 1269
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
IS - 9
ER -
